Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.6 USD | +0.28% | +2.61% | -3.20% |
Mar. 13 | Top Premarket Decliners | MT |
Mar. 12 | JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating | MT |
Financials (USD)
Sales 2024 * | 3.15M | Sales 2025 * | 8.12M | Capitalization | 381M |
---|---|---|---|---|---|
Net income 2024 * | -164M | Net income 2025 * | -238M | EV / Sales 2024 * | 121 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 46.9 x |
P/E ratio 2024 * |
-2.37
x | P/E ratio 2025 * |
-1.71
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.46% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | +0.28% | ||
1 week | +2.61% | ||
Current month | -22.29% | ||
1 month | -6.61% | ||
3 months | +1.83% | ||
6 months | +15.72% | ||
Current year | -3.20% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 12-03-31 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 20-05-31 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 20-05-31 |
David Hallal
CHM | Chairman | 57 | 18-05-31 |
Director/Board Member | 52 | 18-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 29 M€ | -4.59% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 10.6 | +0.28% | 171,996 |
24-04-24 | 10.57 | -3.82% | 148,466 |
24-04-23 | 10.99 | +1.85% | 300,673 |
24-04-22 | 10.79 | +2.18% | 182,392 |
24-04-19 | 10.56 | +2.23% | 943,393 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.20% | 381M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.64% | 22.02B | |
-17.84% | 20.9B | |
-9.19% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- ITOS Stock